Herantis Pharma PLC · OMXHEX:HRTIS

Herantis Pharma — Investor Presentation (December 2020)

28 slides from Herantis Pharma's investor presentation, Dec 16, 2020

  1. Slide 1: Herantis Pharma Company Presentation

    Herantis Pharma Company Presentation 16 December 2020

  2. Slide 2: Disclaimer

    Disclaimer By accepting to receive this presentation from Herantis Pharma Plc (the "Company"), you agree to be bound by the following conditions. This presentation and any oral communication in connection with it (the "Information") are strictly confidential and are being provided to you solely for

  3. Slide 3: Herantis Pharma at the Forefront of Biologic & Gene Therapies

    Herantis Pharma at the Forefront of Biologic & Gene Therapies Company Background • Founded in 2008 in Helsinki, Finland • Listed on Nasdaq First North Finland & Sweden • Assets originate from world leading research at University of Helsinki - Published in top tier journals Regenerative Disease Modif

  4. Slide 4: Focused Pipeline Targeting Unmet Medical Needs

    Focused Pipeline Targeting Unmet Medical Needs Drug Candidate/ Research/ Next Anticipated Indication Discovery Phase 1 Phase 2 Phase 3 Market Potential Project Preclinical Milestone • Met Primary Endpoints #1. Parkinson's Disease (CED device at 12-Month Approx. need for surgery) • Expanding to new r

  5. Slide 5: Experienced Leadership Team to Lead Herantis to Success

    Experienced Leadership Team to Lead Herantis to Success The Key Ingredient to Building a Successful Bioscience Company Craig Cook Tone Kvåle Antti Vuolanto Henri Huttunen Chief Executive Officer Chief Financial Officer Chief Operating Officer Chief Scientific Officer MD, MBA CA D. Sc PhD Serial CEO

  6. Slide 6: Parkinson's Disease & Other Neurodegenerative Diseases CDNF & xCDNF

    Parkinson’s Disease & Other Neurodegenerative Diseases CDNF & xCDNF 6

  7. Slide 7: Significant Unserved Market Needing Disease Modifying Treatments

    Significant Unserved Market Needing Disease Modifying Treatments Total Neurodegenerative Disease Market 2018 Current Treatments Cause Undesirable Side- Estimated $35 Billion, Projected $63 Billion 2026; Effects and Only Somewhat Manage Symptoms CAGR of 7.2% 2 CDNF & xCDNF’s Disease Modifying Regener

  8. Slide 8: A Word on the Mechanism of Action CDNF & Proteostasis

    A Word on the Mechanism of Action CDNF & Proteostasis Proteins are the building blocks of everything in the body. Functionality of all cells (particularly neurons) depends on the balance of the three cornerstones of proteome regulation: synthesis, folding and degradation. If any of these becomes dys

  9. Slide 9: Key CDNF Target is the Endoplasmic Reticulum, the Largest Organelle in Cells

    Key CDNF Target is the Endoplasmic Reticulum, the Largest Organelle in Cells Proteostasis – Remember The Word Nucleus CDNF’s Endoplasmic Big Reticulum (ER)* Ally Cell Membrane 9

  10. Slide 10: CDNF First-in-Human Study

    CDNF First-in-Human Study Main Study – 6 Months Extension Study – 6 Months Follow-up Study – 4 Years Mid-dose CDNF Treatment groups Vehicle (n=6) High-dose CDNF Safety follow-up All patients Mid-dose CDNF (n=6) High-dose CDNF (n=5) Monthly Infusions x 6 Monthly Infusions x 6 Safety Follow-up, No Inf

  11. Slide 11: Primary Endpoint Met

    Primary Endpoint Met Majority of the Reported Drug-Related TEAE’s Were Mild And Have Recovered Similar Safety Profile in Main (0 – 6 Months) And Extension (6 – 12 Months) Study Similar Safety Profile Between Dose-Groups “In addition to the study’s favourable safety profile, it is encouraging to obse

  12. Slide 12: Solid Foundation for a Winning CDNF Program

    Solid Foundation for a Winning CDNF Program Three Key Pillars Develop Standalone CDNF Accelerate Development and Target Earlier Stage Patients Product Time to Partnerability • Move away from invasive surgical • Administration routes focus on • Expand target population to earlier drug-device combinat

  13. Slide 13: Leveraging Proteostasis + Blood Brain Barrier Traversal

    Leveraging Proteostasis + Blood Brain Barrier Traversal Three Key Programs Intranasal Subcutaneous 1 2 3 xCDNF (Nose-to-Brain) (Skin) Routes of Administration Molecular Portfolio Parkinson’s Disease and Chronic Neurodegenerative: Acute Neurodegeneration (such as Stroke & Reperfusion): In Parkinson’s

  14. Slide 14: Nose-to-Brain Administration for Parkinson's & Neurodegenerative Conditions

    1. Nose-to-Brain Administration for Parkinson’s & Neurodegenerative Conditions Direct Pathway Between Olfactory/Trigeminal Neuroepithelium Nasal Mucosa And Brain Striatum Four Key Factors Determine The Efficiency: DOSING DEVICE • Lipophilicity of the Drug Optimized: typically low for proteins 1 Targ

  15. Slide 15: Skin Injection for Acute Neurodegenerative Conditions

    2. Skin Injection for Acute Neurodegenerative Conditions 1. Damage Due to Ischemia Disrupts Blood Brain 3. CDNF Administered Systemically, Crosses Barrier (BBB) Membrane Permeability Compromised BBB to Exert Effect 2. Cytotoxic and Vasogenic Mechanisms Break 4. Pre-clinical Data Supports I.V. and S.

  16. Slide 16: xCDNF A Compelling Asset in Parkinson's Disease

    3. xCDNF A Compelling Asset in Parkinson’s Disease Potential Indications in Parkinson’s Disease and Several Other Neurodegenerative Diseases CDNF Results Provide Solid Platform for xCDNF (Small Engineered Fragments of xCDNF CDNF) • Retain the biological activity of CDNF • Penetrate the BBB • Highly

  17. Slide 17: Potency: xCDNF Retains Potency of CDNF (in vitro)

    Potency: xCDNF Retains Potency of CDNF (in vitro) xCDNF Lead Compound’s Maximum Effect for In Vitro Neuroprotection at 0.5 nM INCREASED NEURONAL SURVIVAL REDUCED ALPHA-SYNUCLEIN AGGREGATION STUDY: Rat mesencephalic neuron cultures treated with 4 µM MPP+ and increasing concentrations of either CDNF o

  18. Slide 18: Other Proteostasis Players: We Are in Good Company

    Other Proteostasis Players: We Are in Good Company Prothena / Roche Yumanity Calico Labs Denali • Prasinezumab (PRX002/R • Originates from • Preclinical, Google- • Deep pipeline addressing G7935), an alpha-synuclein MIT research, early backed company focusing neurodegenerative mAb, is currently in P

  19. Slide 19: Herantis Assets Target Positioning in the Market

    Herantis Assets Target Positioning in the Market 19

  20. Slide 20: Secondary Lymphedema and Other Lymphatic Disease VEGF-C Lymfactin

    Secondary Lymphedema and Other Lymphatic Disease VEGF-C Lymfactin® 2 0

  21. Slide 21: Our Novel Gene Therapy Targets Breast Cancer Related Lymphedema (BCRL)

    Our Novel Gene Therapy Targets Breast Cancer Related Lymphedema (BCRL) Currently Efficacious Therapies, No Cure or Up to 200 Million Patients Suffer From Disease-Modifying Treatments on the Market. Lymphedema Worldwide, Either due to Infection Decompressive Care Still Mainstay of Therapy in (50%) or

  22. Slide 22: Vascular Endothelial Growth Factor (VEGF) a Potent Ubiquitous Growth Promoter

    Vascular Endothelial Growth Factor (VEGF) a Potent Ubiquitous Growth Promoter VEGF-A-F for Blood Vessels VEGF–C for Lymph Vessels L Y M Receptor Receptor Receptor Receptor F A C BLOOD LYMPH T I VESSEL VESSEL VEGFR-1 VEGFR-2 VEGFR-3s VEGFR-3l N Source: Rauniyar K, Biology of Vascular Endothelial Grow

  23. Slide 23: Lymfactin has Potential to be First Medical Therapy for Lymphedema

    Lymfactin® has Potential to be First Medical Therapy for Lymphedema As a part of breast cancer treatments, axillary (armpit) lymph nodes are often removed. This results in compromised lymph flow. Radiation therapy may also harm the lymphatics. Lymfactin® VEGF-C gene therapy is administered locally i

  24. Slide 24: Lymfactin Development on Track

    Lymfactin® Development on Track Phase I Study Safety Established and Maintained • Data confirms safety and tolerability maintained through 24 months • Was not an efficacy study (no control group), nevertheless encouraging improvements observed in signs & symptoms of LE at 12- and 24- month follow-up

  25. Slide 25: Summary

    Summary 2 5

  26. Slide 26: Herantis Development Milestones & Newsflow

    Herantis Development Milestones & Newsflow Commercialization tion Approval ra s Du H2 2021: Further details and next steps ear Phase III (Safety & Efficacy) Y g 10 erin for Lymfactin® – 5 artn Phase II ( Safety & Efficacy) H1 2021: Data readout Phase II P Lymfactin Lymfactin® Phase I (Safety & Dosag

  27. Slide 27: Key Investment Highlights

    Key Investment Highlights 1 Clinical Stage Biotech Company with Multiple Projects Cutting Edge Science in Biological and Gene Therapy that we Have 2 Successfully Moved from Science Into Humans Potential Significant Impact on Diseases that Have Shown Limited Progress 3 in Decades Highly Skilled Team

  28. Slide 28: Thank You!

    Thank You! 2 8

Herantis Pharma — Investor Presentation (December 2020) on 6ix